BeiGene: BRUKINSA Approved in the U.S. for Chronic Lymphocytic Leukemia

Two global Phase 3 trials in adult CLL patients demonstrated superior efficacy for BRUKINSA (zanubrutinib) in first-line and relapsed/refractory treatment settings BRUKINSA is the only BTKi to demonstrate

Related Keywords

China ,Australia ,United States ,New Zealand ,Beijing ,Lugano ,Ticino ,Switzerland ,Cambridge ,Cambridgeshire ,United Kingdom ,American ,Mehrdad Mobasher ,Kevin Mannix ,Brian Koffman ,Kyle Blankenship ,Exchange Commission ,Janssen Biotech Inc ,American Society For Hematology ,Drug Administration ,Business Wire ,Chief Medical Officer ,Executive Vice President ,Lugano Classification ,Clinical Oncology ,Annual American Society ,New England Journal ,Prescribing Information ,Patient Information ,Private Securities Litigation Reform Act ,Janssen Biotech ,Versus Ibrutinib ,Refractory Chronic Lymphocytic Leukemia ,Small Lymphocytic Lymphoma ,Interim Analysis ,Randomized Phase ,Refractory Chronic Lymphocytic ,Final Analysis ,Bendamustine Rituximab ,Chronic Lymphocytic ,Beigene ,Brukinsa ,Approved ,Hronic ,Lymphocytic ,Leukemia ,